Executive Team:

- Dr. Guillaume Kellermann, PhD, Inventor of the Technology, Founder, CEO/CTO.

Guillaume defended his PhD thesis about the natural transducing ability of telomerase in 2009 (mentor Pr. Michelle Hadchouel, Paris-Diderot University), and performed a 2-year post-doctoral training working on lentiviral vectors at the Institute of Emerging Diseases and Innovative Therapies(IMETI) directed by Dr. Philippe Leboulch, at the Commissariat à l'Energie Atomique (CEA). In 2011, he joined the UMR-1007 at the Paris-Descartes University in the group of Dr. Sophie Bombard, where he has mainly worked on telomerase-related projects funded by the SATT IDFINNOV, in collaboration with the Curie Institute. In 2016, he joined the laboratory directed by Pr. Nicolas Leulliot at the Faculty of Pharmacy of Paris-Descartes University to set the production of telomerase in fermentor, and founded Telomium.

- Dr. Nicolas Ferry, MD, PhD. Regulatory & Clinical Affairs.
After a PhD in endocrinology at the Pierre and Marie Curie University and a MD at Necker Hospital in Paris, he led an INSERM research laboratory in the field of gene therapy. Among his projects, he developed a DNA cancer vaccine  and started a clinical trial in immunotherapy for hepatocellular carcinoma. In 2011, he joined the French regulatory agency (then Afssaps and now ANSM) where he was in charge of a division dedicated to vaccines, products of human origin and advanced therapies; and he was also the France's representative at the CAT (Committee for Advanced Therapies) at EMA in London. In 2016, he left the agency and founded a small advisory company, NF Consulting, dedicated to scientific, medical and regulatory advises. Nicolas worked for Servier, and is VP and Chief Development Officer art Horam (gene therapy). He met Telomium in 2015 before our creation.

Industrial/Business Advisors:

- Dr. Jean Smal, PhD. ex Vice-President at GSK vaccines.

Director of the CMO Eurogentec (1989-1988), Jean joined GSK in 1999 and became Vice-President Head of New Products Development (2012-2014) at GLAXOSMITHKLINE VACCINES. Since 2016, he now works mainly as a consultant for biotech companies. He met Telomium in 2018 and agreed to advise us in the technical development of our product.

- Dr. Kevin Adam, PhD. Life Science Business development.

Globe-trotter and Business developer for Industry & Academia Partnerships. Kevin was CEO of French Biobeach, a platform promoting partnering between California and Europe. Kevin was also scientific collaborator at the Salk Institute and the Scripps Research Institute (La Jolla). He obtained a bachelor in innovation management (Global Innovation Management Institute). After a master in Oncology (ENS Cachan), he got a PhD (Cochin hospital) and a post-doc in Tony Hunter’s lab (Salk Institute).

Clinical Advisors:

- Professor François-Clément Bidard.

Medical oncologist at the Institut Curie, Professor of Medicine (PU-PH) at the University of Versailles Saint-Quentin / Paris-Saclay. His clinical activity is mainly focused on breast cancer but also other types: gynecological, digestive, melanoma, carcinoma of unknown origin... His research activity concerns the characterization of the mechanisms at work during the metastatic process and particularly the detection of tumor biomarkers detectable in the blood (circulating tumor cells; circulating tumor DNA, etc.).